The Cost-Effectiveness of Sugemalimab Plus CAPOX in Treating Advanced Gastric Cancer: Analysis from the GEMSTONE-303 Trial
Sugemalimab plus CAPOX is not cost-effective for advanced or metastatic G/GEJ adenocarcinoma from the Taiwan payer's perspective. Achieving cost-effectiveness would require a 20-30% price reduction for sugemalimab (to USD 1204-USD 1376 per 600 mg), assuming first-line therapy is administered for the median treatment duration observed in the GEMSTONE-303 trial. If reimbursement continued until disease progression, a reduction of approximately 68% would be required (USD 550 per 600 mg).
Authors
- Hsiao‐Ling Chen (ORCID: https://orcid.org/0000-0001-7544-2178)
- Chen‐Han Chueh (ORCID: https://orcid.org/0000-0002-3337-2586)
- Nai‐Jung Chiang (ORCID: https://orcid.org/0000-0003-2743-9702)
- Ming-Yu Hong
- Yi‐Wen Tsai (ORCID: https://orcid.org/0000-0003-1422-7217)
- Wei‐Ming Huang (ORCID: https://orcid.org/0000-0002-3709-1095)
Institutions
- National Yang Ming Chiao Tung University (TW)
- National Health Research Institutes (TW)
- Taipei Veterans General Hospital (TW)
- University of California San Diego (US)
- Human Longevity (United States) (US)
Publication Details
- Journal
- Cancers
- Published
- 2025-09-29
- DOI
- https://doi.org/10.3390/cancers17193171
- Citations
- 2
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 3.04